Podcasts about Gilead

This week on Sinica, a rare treat: an in-person recording from Beijing with two dear friends who happen to be two of the very best in the business on technology and China — Samm Sacks and Paul Triolo, fresh off the exhibition floor of the World Artificial Intelligence Conference in Shanghai. We dig into Xi Jinping's first in-person WAIC appearance and his most extensive statement on AI to date, the launch of the World AI Cooperation Organization, Moonshot's release of Kimi K3, the Trump administration's reported push to shut Chinese open-weight models out of the U.S. market, the coming age of agents, the untranslatable problem of ānquán, and what to expect from the first U.S.-China AI dialogue in September.8:51 – The view from the floor: heat, humidity, robot boxing grandmas, WeChat-gated free water, and the "AI+" vibe — why WAIC 2026 felt less like an AI conference than a sector-by-sector snapshot of China's entire economy being supercharged with AI, with attendance swelling to some 200,000 tickets16:32 – Why Xi showed up: what the leader's first in-person WAIC appearance and his most extensive AI statement to date signal, and why domestic drivers matter as much as geopolitics18:01 – Chapter and verse: which phrases from the speech will be put to work in the system — "secure and orderly development" and the governance of agents, and Xi's strikingly extensive language on AI safety after China was frozen out of the Paris process22:26 – The ānquán problem: one word meaning both "safety" and "security," the three buckets of AI risk, and how China's safety community has moved from bias and deepfakes toward CBRN and loss-of-control concerns — Black Mirror versus Star Trek28:14 – Shanghai's baby: how WAIC's ownership structure differs from the CAC-run World Internet Conference in Wuzhen, Chen Jining's very visible host duties, and whether the center of gravity in AI policy is shifting to the Yangtze River Delta30:05 – WAICO: what the new World AI Cooperation Organization with its 29 founding members is actually for, Xi's concrete deliverables for the Global South — 5,000 AI training slots, regional cooperation centers, the MAZU early-warning system — and healthy skepticism about follow-through34:39 – Kimi K3: what's technically significant in Moonshot's big new model, why it's the fourth arguably frontier-class Chinese release in a single month, the two-way traffic in distillation accusations, and what it all says about the state of the frontier gap four years into export controls40:33 – Washington reacts: the reported menu of options for shutting Chinese open-weight models out of the U.S. — entity listings, a draft executive order, supply-chain security authorities — and why none of the tools actually fit the problem49:36 – Strange bedfellows: David Sacks versus the "closed lab duopoly," the FUD strategy, why some 80% of Andreessen Horowitz portfolio companies reportedly run on Chinese open models, and how gating U.S. frontier models while Chinese weights flow freely supercharges the AI sovereignty argument worldwide54:55 – The model is infrastructure, the agent is the product: the ByteDance–ZTE agentic phone, the CAC's new initiative on agent trust and interoperability, and why agents fused into operating systems upend both super-app walled gardens and China's data protection regime1:02:27 – An exegesis of kěkòng: the many meanings of "controllable," the long history of ānquán kěkòng in Chinese tech policy, and the unanswered question of who — CAC, NDRC, or somebody new — actually owns AI safety in either system1:08:54 – The road to September: what to expect from the first U.S.-China AI dialogue, why Mythos tops the Chinese grievance list, the securitization feedback loop that starves trust-and-safety advocates of resources on both sides, and why recursive self-improvement makes this feel like a last, best chancePaying It ForwardPaul nominates Tony Peng, whose Substack RecodeChinaAI offers sharp, well-written analysis of the application side of China's AI industry — part of an impressive new generation of independent China tech writers. Samm gives a shout-out to Professor Zhu Yue of Tongji University Law School, published in Science and doing pioneering work at the intersection of disability law and AI law.RecommendationsSamm: The Land and Its People by David Sedaris — laugh-out-loud funny, especially the "Enough is Enough" chapter; Transcription by Ben Lerner, a perfect small novel about fathers, sons, memory, and technology as enabler or disabler of connection; and Didion and Babitz, on Joan Didion and Eve Babitz and the 1970s California rock scene.Paul: The Party's Interests Come First by Joseph Torigian — dense but beautifully written, and essential for understanding the current Chinese leadership.Kaiser: A fiction-only summer! Stoner by John Williams, a small life told most grandly in some of the most beautiful sentence-level writing anywhere; Gilead by Marilynne Robinson, an epistolary novel dense with distilled wisdom from a dying Iowa minister; and Wang Xiaobo's The Golden Age (黄金时代) in Yan Yan's excellent new translation — bawdy, hilarious, and super Beijing-y despite its Cultural Revolution setting.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In Episode 229, Sarah talks with Laura B. McGrath about her new book, Middlemen, and the behind-the-scenes role literary agents play in publishing. They discuss what agents actually do, how they shape an author's career, the hype surrounding debut novels, and what Laura learned while researching one of publishing's least visible professions. Plus, Laura shares her book recommendations. This post contains affiliate links through which I make a small commission when you make a purchase (at no cost to you!). CLICK HERE for the full episode Show Notes on the blog. Highlights Middlemen by Laura B. McGrath (April 28) | Amazon | Bookshop.org  Why a literary agent's most important job isn't what most readers think. What agents are really looking for when they decide to represent an author. The surprising amount of homework agents do before signing a new client. The hype surrounding debut novels — and some of the downsides that come with it. Why the publishing industry was initially wary of public book sales data. Laura's Book Recommendations Two OLD Books She Loves Housekeeping by Marilynne Robinson (1980) | Amazon | Bookshop.org [45:12]  Franny and Zooey by J. D. Salinger (1961) | Amazon | Bookshop.org  [47:59]  Other Books Mentioned   Gilead by Marilynne Robinson (2004) [46:36]  Two NEW Books She Loves London Falling by Patrick Radden Keefe (April 7) | Amazon | Bookshop.org[49:25]  Discipline by Larissa Pham (Jan 20) | Amazon | Bookshop.org [51:42]  Other Books Mentioned  Say Nothing by Patrick Radden Keefe (2018) [50:31]  One Book She DIDN'T Love The Ending Writes Itself by Evelyn Clarke (April 7) | Amazon | Bookshop.org[53:14]  Other Books Mentioned Erasure by Percival Everett (2001) [53:30]  The Wife by Meg Wolitzer (2003) [53:32]  And Then There Were None by Agatha Christie (1939) [54:16] The Mousetrap by Agatha Christie (1947/1952) [54:19]   Yellowface by R. F. Kuang (2023) [55:34]  One NEW RELEASE She's Excited About Music Against the Night by Yiyun Li (October 13, 2026) | Amazon | Bookshop.org [57:04] Sneak Pick: Miss Lambert Steps Aboard Danger by Kazuo Ishiguro (March 9, 2027) | Amazon | Bookshop.org  [57:04]  Other Books Mentioned Things in Nature Merely Grow by Yiyun Li (2025) [57:39]  The Unconsoled by Kazuo Ishiguro (1995) [58:43]  The Remains of the Day by Kazuo Ishiguro (1989) [59:27]  Books From the Discussion The Middle Man by Paul R. Reynolds (1972) [3:09] Talking at Night by Claire Daverley (2023) [10:40] Zone One by Colson Whitehead (2011) [11:20] Catch-22 by Joseph Heller (1961)  [12:36]  Mila 18 by Leon Uris (1961) [13:33] The Intuitionist by Colson Whitehead (1999) [14:18] Station Eleven by Emily St. John Mandel (2014) [33:52]  Tomorrow, and Tomorrow, and Tomorrow by Gabrielle Zevin (2022) [34:28]  The God of the Woods by Liz Moore (2024) [34:34]  Long Bright River by Liz Moore (2020) [34:36]  The Unseen World by Liz Moore (2016) [34:39] 

The Recfest Recap 2026   We're unpacking the absolute best moments, groundbreaking strategies, and actionable takeaways from RecFest 2026. Whether you were dodging the summer sun at Knebworth Park or couldn't make it across the pond, this exclusive recap session distills the high-impact content from the industry's top thought leaders. Get ready to supercharge your TA strategy, embrace the human advantage in an AI-driven world, and discover exactly what the future of recruitment looks like.   The Human Advantage in an AI World: Grace Lordan (LSE) explores how talent leaders can leverage AI, inclusion, and better decision-making to drive true performance rather than just processing efficiency.   From Recruiter to Talent Architect: A powerhouse panel featuring leaders from Amazon, EY, and Booking.com discusses the evolution of the recruiter role as AI absorbs operational tasks, shifting the focus to high-value, human-centric strategy.   The AI-Adjusted EVP: Joanna Hackett (Howden) reveals how forward-thinking organisations are evolving their Employee Value Propositions to focus on reskilling, internal mobility, and long-term career relevance in the age of automation.   TA as a Strategic Growth Engine: Chris Tennant (Infor) and fellow TA directors from Gilead and Mars share how to fundamentally redesign the talent acquisition function to operate as a core driver of business performance.   Amazon's Strategic Business Partner Model: Beckie Longworth and the Amazon TA team reveal how they shifted from a transactional, requisition-driven service into a strategic business partner function that acts as a consistent interface for growth.   Talent Intelligence at Scale: Andrew Sinclair and Charles Rue (S&P Global) demonstrate how to build a connected workforce by turning overwhelming talent data into actionable, confident market intelligence.   The Early Careers Talent Crisis: Aisha Lysejko (2040 Leaders) and experts from Shell and Danone warn against cutting early careers investments, explaining how doing so creates a dangerous "missing middle" that cripples future leadership pipelines.   Standardised Hiring Metrics: Adrian Thomas (Walbridge) and Jonathan Berry (House of Commons) break down the UK's first standardised hiring metrics, exploring what "good" really looks like in talent acquisition benchmarking today.   Global TA Transformation at Sanofi: Lia Manafova (Sanofi) shares the healthcare giant's journey of taking back ownership of their global recruitment landscape, transitioning away from decentralized models to centralise and streamline their tech stack.   Why should you carve out time in your busy schedule to join 'The Recfest Recap 2026'? Because the recruitment landscape is shifting faster than ever, and relying on yesterday's playbooks simply won't cut it. This webinar isn't just a summary; it's your shortcut to the strategies that are actively reshaping the industry—from deploying AI without losing the human touch to transforming TA into a strategic business partner. By signing up, you'll equip yourself with the tangible, future-proof tactics you need to attract top talent, elevate your employer brand, and lead your team into the next era of hiring. Secure your spot now and stay ahead of the curve!   We're on Wednesday 8th July at 2pm BST. Register by clicking on the green button (save your spot) and follow the channel here (recommended).   Ep392 is supported by our friends at Screenloop   Screenloop is the number one ATS for SMEs: covering interview intelligence, background checks, automations, candidate NPS and Quality of Hire analytics, all-in-one package.   Rated 4.9/5 on G2 our Interview Intelligence transcribes, fills scorecards, coaches hiring teams, so every hiring decision is faster, fairer and evidence-based. Importantly, our AI tools do hallucinate or over promise, it improves human led conversations.

1 Samuel 13:1-8 (KJV) Saul reigned one year; and when he had reigned two years over Israel, 2 Saul chose him three thousand men of Israel; whereof two thousand were with Saul in Michmash and in mount Beth-el, and a thousand were with Jonathan in Gibeah of Benjamin: and the rest of the people he sent every man to his tent. 3 And Jonathan smote the garrison of the Philistines that was in Geba, and the Philistines heard of it. And Saul blew the trumpet throughout all the land, saying, Let the Hebrews hear. 4 And all Israel heard say that Saul had smitten a garrison of the Philistines, and that Israel also was had in abomination with the Philistines. And the people were called together after Saul to Gilgal. 5 And the Philistines gathered themselves together to fight with Israel, thirty thousand chariots, and six thousand horsemen, and people as the sand which is on the sea shore in multitude: and they came up, and pitched in Michmash, eastward from Beth-aven. 6 When the men of Israel saw that they were in a strait, (for the people were distressed,) then the people did hide themselves in caves, and in thickets, and in rocks, and in high places, and in pits. 7 And some of the Hebrews went over Jordan to the land of Gad and Gilead. As for Saul, he was yet in Gilgal, and all the people followed him trembling. 8 And he tarried seven days, according to the set time that Samuel had appointed: but Samuel came not to Gilgal; and the people were scattered from him.

This episode of All Pop, No Culture opens with a full-panel argument about Supergirl. Andrew hated it, Kevin liked it, and Eric landed in the middle, making this one of the most divided reviews the show has had in a while. The conversation covers tone, villains, Lobo, Ruthie, Kara's arc, and whether the backlash is really about the movie itself or something else entirely. Lauren then reviews The Testaments on Hulu, the continuation of The Handmaid's Tale, and explains why it feels sharper, darker, and more emotionally grounded than the later seasons of the original series. Kevin joins in with thoughts on Aunt Lydia, Agnes, Lucy, and the unsettling world-building that still makes Gilead feel terrifyingly plausible. Andrew also gives his first reaction to Backrooms, Kevin defends its atmosphere and sequel potential, and Eric spotlights Bang My Box: Robin Byrd, a documentary about a public-access TV pioneer who helped push sexuality and LGBTQ visibility into the mainstream before the internet existed.

On this podcast episode, we spotlight our IPhO Annual Meeting Premier Sponsor, the USC Mann Pharmaceutical Industry Fellowship Program. We are joined by Michael Lim, USC Fellowship Director; along with former fellows Keya Patel, who transitioned from Gilead's Global Medical Affairs HIV Prevention Fellowship to a Global Medical Affairs strategy role in HIV Treatment; and Trey Graham, who transitioned from AbbVie's Medical Affairs Evidence Planning and Execution Fellowship to a Dermatology Medical Science Liaison role. Michael, Keya, and Trey discuss the USC fellowship experience, highlighting the program's supportive structure, professional development opportunities, and resources that help fellows successfully transition into full-time roles. They also share practical advice on taking initiative, setting expectations with preceptors, building meaningful professional relationships, and maximizing the fellowship experience.  Whether you're just starting pharmacy school, finishing your fellowship, or preparing to launch your career, this episode is packed with insights you won't want to miss!

Fake Repentance Hosea 6 6 “Come, let us return to the LORD; for he has torn us, that he may heal us; he has struck us down, and he will bind us up. 2  After two days he will revive us; on the third day he will raise us up, that we may live before him. 3  Let us know; let us press on to know the LORD; his going out is sure as the dawn; he will come to us as the showers, as the spring rains that water the earth.” 4  What shall I do with you, O Ephraim? What shall I do with you, O Judah? Your love is like a morning cloud, like the dew that goes early away. 5  Therefore I have hewn them by the prophets; I have slain them by the words of my mouth, and my judgment goes forth as the light. 6  For I desire steadfast love and not sacrifice, the knowledge of God rather than burnt offerings. 7  But like Adam they transgressed the covenant; there they dealt faithlessly with me. 8  Gilead is a city of evildoers, tracked with blood. 9  As robbers lie in wait for a man, so the priests band together; they murder on the way to Shechem; they commit villainy. 10  In the house of Israel I have seen a horrible thing; Ephraim's whoredom is there; Israel is defiled. 11  For you also, O Judah, a harvest is appointed. When I restore the fortunes of my people,

Superstar actor Lukas Gage stopped by the Page Six studio to chat with "Virtual Reali-Tea" co-hosts Danny Murphy and Evan Real about his partnership with Gilead for their HealthySexual campaign, and of course, we had to get into his favorite reality shows. The Bravoholic shared his honest thoughts on everything from his "look-alike," Vicki Gunvalson's return to "Real Housewives of Orange County," to which reality show he'd give all to join. Lukas also discussed his upcoming film featuring the icon Pamela Anderson. Check out the full unedited interview now! Follow us on Instagram! Sign up for our newsletter! Check us out on YouTube! Head to our show page for more tea! Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the dynamic shifts and breakthroughs shaping the industry, from major acquisitions to groundbreaking scientific advancements. Merck KGaA has made headlines with its bold $11.3 billion acquisition of Bio-Techne Corporation. This marks Merck's most significant deal since purchasing Sigma-Aldrich in 2015, reinforcing its strategic focus on expanding its life sciences tools portfolio. The acquisition aims to accelerate innovation in drug development and diagnostics, highlighting Merck's commitment to enhancing its capabilities in biotechnology under the leadership of CEO Kai Beckmann. Such strategic moves underscore a broader trend towards bolstering biotech portfolios through mergers and acquisitions as companies aim to remain competitive in an ever-evolving market landscape. In regulatory news, the FDA has approved a pioneering combination therapy involving Gilead's Trodelvy and Merck & Co.'s Keytruda for the first-line treatment of triple-negative breast cancer (TNBC). This aggressive cancer subtype has historically had limited treatment options, making this approval particularly significant. The combination therapy leverages an antibody-drug conjugate targeting Trop-2 alongside a PD-1 inhibitor, offering a promising new strategy that could substantially improve patient survival outcomes. This development also highlights the growing role of antibody-drug conjugates in oncology, illustrating how innovative therapeutic combinations can enhance treatment efficacy. Meanwhile, Pfizer's Ibrance has received FDA approval for label expansion to treat HR-positive, HER2-positive metastatic breast cancer. As a CDK4/6 inhibitor crucial in cell cycle regulation, Ibrance's expanded use reflects ongoing advancements in targeted therapies that personalize cancer treatment based on specific molecular characteristics. Such expansions demonstrate the importance of continuous clinical evaluation and regulatory engagement in extending the lifecycle and applications of existing drugs. Ionis Pharmaceuticals has gained FDA approval for Tryngolza for severe hypertriglyceridemia, marking a significant milestone for antisense oligonucleotide therapies. By targeting apolipoprotein C-III, Tryngolza offers a novel approach to managing metabolic conditions linked to pancreatitis risks. This approval underscores the growing importance of antisense technology in addressing complex lipid disorders and highlights Ionis' strategic efforts to expand market reach through global partnerships. On the business development front, Boehringer Ingelheim's partnership with Immunai aims to leverage artificial intelligence in T-cell target discovery for cancer and autoimmune diseases. The integration of AI/ML technologies into drug discovery processes is increasingly seen as essential for enhancing precision and efficiency. This collaboration reflects an industry-wide shift towards embracing technology to improve research and development outcomes. In clinical trials, Otsuka's centanafadine shows promise for adults with ADHD and comorbid anxiety following successful Phase 3b trials. As a small molecule reuptake inhibitor, centanafadine could provide dual therapeutic benefits for patients with these overlapping conditions. Such developments highlight ongoing innovation in neuropsychiatric treatments aimed at addressing mental health conditions with greater precision. Financially, Oblenio Bio's $62 million Series B funding round will support advancing its tri-specific autoimmune T-cell engager into trials, potentially offering new solutions for autoimmune diseases through innovative immunotherapy approaches. These financial movements illustrate how companies are strategically positioning themselves to capitalize on emerging therapeutic opportunities. Amid these developments, regulatory dynamics continue to evolve, as seen with the FDA's pilot program aimed at streamlining drug approval processes. Initiatives like these are pivotal in restoring confidence in regulatory frameworks while adapting to new scientific insights and technological advancements. Overall, these developments underscore the pharmaceutical and biotech sectors' dynamic nature, characterized by strategic collaborations, regulatory milestones, and innovative treatment options poised to enhance patient care and strengthen drug development pipelines. The ongoing integration of cutting-edge technologies such as AI signifies an evolution towards more personalized and efficient healthcare solutions. Thank you for tuning into Pharma Daily, where we bring you the latest insights from the forefront of pharmaceutical and biotech innovation. Join us next time as we continue to explore the trends shaping the future of healthcare globally.Support the show

Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

────────────────────────────────────────[00:02:09]Trump Unilaterally Rewrites the MOU — Demands Iran Spend Frozen Funds Only on US Farm GoodsPoint 11 of the signed MOU says funds are released without conditions; Trump invented the escrow-for-American-corn clause after Kushner pressed him.────────────────────────────────────────[00:05:00]Senate Votes to Halt the Iran War — Resolution Has No Force of Law, White House Dismisses ItPassed 50-48; does not go to the president for signature or veto; four Republicans broke ranks including Rand Paul and Bill Cassidy.────────────────────────────────────────[00:10:18]Ben Gvir: All of Lebanon Must Be Our Playground — For Every Israeli Tear, a Thousand Lebanese Must WeepIsraeli finance minister refuses any restriction on Lebanese territory and demands it all burn; Netanyahu confirmed forces are not leaving.────────────────────────────────────────[00:46:01]Rand Paul's Wife Bought Gilead Stock During Remdesivir Push — Knight Says He Has No Credibility on FauciFauci declared remdesivir standard of care one day after a WHO trial showed it ineffective; Paul's wife held Gilead shares throughout.────────────────────────────────────────[00:47:41]Trump Orders Ford and GM to Make Bombs Instead of Cars — Same Defense Production Act Used for VentilatorsKnight: they don't want people to have independent transportation; commandeering auto production is the same playbook used in 2020.────────────────────────────────────────[00:56:37]VA Study Claims COVID Vaccine Lowers Cardiac Risk — Knight: They Caused the Heart Disease and Now Claim the CureSeven children confirmed dead from the jabs per FDA data; New England Journal of Medicine ex-editor said the journal lost all credibility.────────────────────────────────────────[01:29:16]Tulsi Gabbard's Entire Career Was Guided by a Hare Krishna Cult Leader Named Chris ButlerYear-long Washington Post investigation; former cult members handed over internal records showing Butler shaped her public decisions.────────────────────────────────────────[01:43:44]Ben Gvir Repeats: All of Lebanon Must Burn — No Distinction Between Hezbollah and Lebanese CiviliansSame doctrine applied in Gaza; Knesset member adds they want to drag Hamas leaders across Gaza in front of cameras before prison.────────────────────────────────────────[01:47:00]Jared Kushner Invented the Escrow-for-Farm-Goods Clause — JD Vance Selling It as a Trump DealMOU says nothing about escrow or American goods; Kushner and Qataris fabricated it after signing; Vance repeating the lie publicly.────────────────────────────────────────[01:51:28]Zionist Lobbyist Brags About Sanctioning UN Rapporteur Albanese, Freezing Her Bank Accounts, Demoting Her HusbandAfter boasting of controlling Albanese's finances and barring her from the US, lobbyist Hillel Neuer insists the Jewish lobby does not control America. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

────────────────────────────────────────[00:02:09]Trump Unilaterally Rewrites the MOU — Demands Iran Spend Frozen Funds Only on US Farm GoodsPoint 11 of the signed MOU says funds are released without conditions; Trump invented the escrow-for-American-corn clause after Kushner pressed him.────────────────────────────────────────[00:05:00]Senate Votes to Halt the Iran War — Resolution Has No Force of Law, White House Dismisses ItPassed 50-48; does not go to the president for signature or veto; four Republicans broke ranks including Rand Paul and Bill Cassidy.────────────────────────────────────────[00:10:18]Ben Gvir: All of Lebanon Must Be Our Playground — For Every Israeli Tear, a Thousand Lebanese Must WeepIsraeli finance minister refuses any restriction on Lebanese territory and demands it all burn; Netanyahu confirmed forces are not leaving.────────────────────────────────────────[00:46:01]Rand Paul's Wife Bought Gilead Stock During Remdesivir Push — Knight Says He Has No Credibility on FauciFauci declared remdesivir standard of care one day after a WHO trial showed it ineffective; Paul's wife held Gilead shares throughout.────────────────────────────────────────[00:47:41]Trump Orders Ford and GM to Make Bombs Instead of Cars — Same Defense Production Act Used for VentilatorsKnight: they don't want people to have independent transportation; commandeering auto production is the same playbook used in 2020.────────────────────────────────────────[00:56:37]VA Study Claims COVID Vaccine Lowers Cardiac Risk — Knight: They Caused the Heart Disease and Now Claim the CureSeven children confirmed dead from the jabs per FDA data; New England Journal of Medicine ex-editor said the journal lost all credibility.────────────────────────────────────────[01:29:16]Tulsi Gabbard's Entire Career Was Guided by a Hare Krishna Cult Leader Named Chris ButlerYear-long Washington Post investigation; former cult members handed over internal records showing Butler shaped her public decisions.────────────────────────────────────────[01:43:44]Ben Gvir Repeats: All of Lebanon Must Burn — No Distinction Between Hezbollah and Lebanese CiviliansSame doctrine applied in Gaza; Knesset member adds they want to drag Hamas leaders across Gaza in front of cameras before prison.────────────────────────────────────────[01:47:00]Jared Kushner Invented the Escrow-for-Farm-Goods Clause — JD Vance Selling It as a Trump DealMOU says nothing about escrow or American goods; Kushner and Qataris fabricated it after signing; Vance repeating the lie publicly.────────────────────────────────────────[01:51:28]Zionist Lobbyist Brags About Sanctioning UN Rapporteur Albanese, Freezing Her Bank Accounts, Demoting Her HusbandAfter boasting of controlling Albanese's finances and barring her from the US, lobbyist Hillel Neuer insists the Jewish lobby does not control America. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Chat with Subhi: https://calendly.com/letscombinate/let-s-combinate-intro-sessionFinished medical devices can create a lot of surprises when they are added to combination product kits.A needle, vial adapter, filter, or transfer device may already be sterile, cleared, qualified, and sold at massive scale.But already on the market does not automatically mean ready for your combination product.In this episode, I talk through the challenges of selecting finished medical devices for combination product kits and the three lifecycle moments that usually determine whether qualification goes smoothly or turns into a late-stage problem.We cover:* Why “already approved” does not mean combination-product ready* Why you inherit the supplier's design, QMS, packaging, validation, change control, and outsourcing decisions* What to think about before supplier selection* How to set expectations during supplier selection* Why structured qualification matters* How PPAP concepts like process flow, PFMEA, control plans, inspections, sampling, and validation evidence can helpThe main point: A commercially available device may be qualified for someone else's intended use. Your job is to determine whether it is qualified for yours.Chapters:00:00 Device Selection Stakes02:05 Common Supplier Myths03:54 Inheriting the Device QMS04:53 Three Crucial Moments05:51 Before Selection: Intended Use07:21 Packaging, Markets, and Risk Flags08:55 During Selection: Set Expectations10:33 Qualification: Use a Structured PPAP Approach14:12 Wrap Up and Next StepsSubhi Saadeh is the Founder and Principal at Let's Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, supplier quality, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, and speaker with experience across companies including Pfizer, Gilead, and Baxter, supporting the development and launch of combination products across vaccines, biologics, and generics.Let's Combinate helps teams develop and control drug-device combination products by aligning quality systems, development, supplier quality, and regulatory expectations across drug and device domains.#CombinationProducts #MedicalDevices #PharmaQuality #SupplierQuality #DrugDeviceCombinationProducts #PPAP #QualitySystems

Welcome to The Daily, where we study the Bible verse by verse, chapter by chapter, every day. Grab your Hosea Scripture Journal right now. Our text today is Hosea 6:7-9: But like Adam they transgressed the covenant; there they dealt faithlessly with me. Gilead is a city of evildoers, tracked with blood. As robbers lie in wait for a man, so the priests band together; they murder on the way to Shechem; they commit villainy. — Hosea 6:7-9 Hosea names real locations—Gilead and Shechem. These were not random cities. They were places of spiritual significance. Gilead was associated with covenant land, healing balm, and the inheritance of God's people. Shechem was one of the great covenant sites in Israel's story. Abraham built an altar there. Jacob returned there. Joshua renewed the covenant there. It was a place where people once remembered God's faithfulness. But now what are they? "Gilead is a city of evildoers, tracked with blood." "The priests… murder on the way to Shechem." The names remained, but the meaning had changed. These cities still existed geographically, but spiritually they had become something else. Thus the warning. A place can keep its "holy" name while losing its "holy" character. A city can preserve religious language while celebrating rebellion. A church can keep the sign on the building while abandoning the presence of God. A people can inherit a Christian past while living in practical unbelief. Think about it. How many cities carry church steeples but no fear of God? How many communities bear Christian history but reject Christian truth? How many people wear the label "Christian" while living untouched by Christ? Names do not save. History does not save. Heritage does not save. Only transformation does. The work done at the heart level. God was not impressed by the fact that Gilead used to matter or that Shechem once held covenant memories. He judged them at this moment by what they had become. And God does the same with us. So do not hide behind where you live, where you grew up, what church you attend, or what family you came from. Assess another question: Who am I now? Because the issue is not what your city, church, or life was once called. The issue is whether Christ truly rules there now. Let him reign in you now and forevermore. DO THIS: Pray for your city, church, and home today. Then ask God to begin renewal in you before asking Him to change everyone else. ASK THIS: Am I relying on a Christian label instead of real transformation? Does my life reflect Christ—or just a religious identity? How can I become part of renewal where I live? PRAY THIS: God, forgive us for keeping your name while ignoring your ways. Transform my life, my home, and my city so your name is honored again. Amen. PLAY THIS: "Forever Reign"

In this study we will take a look at the women within the Bible. We will look at each one of them and see how their story influences our lives today.As we continue our study in this fantastic insight of the Women of the Bible, this morning we complete our study on Rachel and LeahNames in the Bible often say something about the person:Rachel means 'ewe', a female sheep, a symbol of prosperity and security for nomadic people Leah means 'weary or wild cow' Jacob means 'heel grabber', either his brother's heel at the moment of birth or his brother's inheritance later on; the name can also mean 'deceiver' Laban means 'white'; it was sometimes linked with leprosy Reuben means 'behold, a son!' Joseph means 'may he add or increase'The story contains five different episodes:   1 Rachel meets Jacob at the well, Genesis 29:1-14 2 Leah and Rachel marry Jacob, Genesis 29:15-30 3 Rachel has a son, Joseph, Genesis 29:31-15, 30:1-24 4 Rachel and Leah leave with Jacob, and Rachel takes the sacred household deities, Genesis 30:25-43, 31 5 Rachel has a son, Benjamin, and dies soon after, Genesis 35:16-30In our last study we learned about Jacob leaving his homeland and traveling to his mother's homeland of Haran to find a wife. There at the well Jacob meets his future wife Rachel. But hold on Rachel as we learned had a older sister Leah. When Jacob went into their father and asks for his daughters hand in marriage, Labin tricks Jacob into marrying Leah instead of Rachel. So we see that Jacob must fulfill his promise to Labin for the hand of Rachel. As the story unfolds we see Leah producing children for Jacob. However we see that Rachel faced a different problem. No matter how she prayed to Yahweh, no matter how much she was loved by Jacob, Rachel did not conceive. In desperation she gave her maid Bilhah [timid, bashful] to Jacob, so that he could conceive a child with Bilhah as a surrogate mother for Rachel. This practice was common in the ancient world [Code of Khammurabi section 145]; the woman became a concubine instead of a servant, and it was a step up the social ladder for her. She might become the mother of the future tribal leader.  Bilhah had a son, whom Rachel named Dan [judge]. Then she had a second son, and Rachel called him Naphtali [my wrestling]. In response, Leah gave her own maid Zilpah [trickling] to Jacob, and this resulted in yet more sons: Gad [troop] and Asher [happy]. A bitter rivalry grew up between the two women.  We pick up our story in Genesis Chapter 30(1-4) Rachel, out of frustration, gives Jacob her maid Bilhah to bear children through her.(5-6) The birth of Dan.(7-8) The birth of Naphtali.(9-11) The birth of Gad.(12-13) The birth of Asher.(14-18) The birth of Issachar.(19-20) The birth of Zebulun.(21) The birth of Dinah.Finally we read in verse 22 that Yahweh remembers Rachel and opens her womb.Verses 23, 24, “She conceived and bore a son and said, 'Elohim has taken away my reproach'; and she named him Joseph (let me add or adding), saying 'May Yahweh add to me another son!'” Rachel and Leah flee with JacobAt this stage, Jacob felt Yahweh calling him to return to his homeland. Rachel and Leah were also dissatisfied by the way things were panning out financially, and felt they are not getting what they were entitled to as Laban's daughters. It was time to go. They both urged Jacob to take action. It seems that Rachel in particular was still angry at her father for what he had done to her. Before they set out, she took the small figurines that represented the spirits of ancestors and the protective deities of her father's family (the teraphim), telling no one at all what she was doing. This was not a random act of malice, for years ago on what should have been her wedding night, Laban had stolen Rachel's happiness. Now she stole something that was precious to him - pay-back for a life-time of bullying. But her act had wider significance than this, because the teraphim (This word occurs only in the plural, and denotes images connected with magical rites. The teraphim, translated, "images", in the Authorized Version, carried away from Laban, by Rachel, were regarded by Laban as elohims, and it would, therefore, appear that they were used by those who added corrupt practices to the patriarchal religion) were a form of title deed, and the person who possessed them could claim the tribe's wealth. Ownership of the household deities was the privilege of the head of the family, and by taking them Rachel secured this position for her husband.  The whole family group assembled; ready to return to the land of Jacob's father, Isaac. They crossed the Euphrates and headed towards the hill country of Gilead. But it was not going to be as easy as that. Laban pursued them, caught up with them, and confronted them. Where were the household elohims? They were missing and Laban wanted them back.  This was news to Jacob. He did not know Rachel had taken them, since she had kept them hidden and had not told anyone what she had done. Jacob then made one of those foolish pronouncements that give the reader a hint that something bad is coming: he indignantly denied knowledge of the theft, and said that whoever had done such a thing should die. Laban searched the tents of Jacob, Leah, and the two maids to find the teraphim- each woman in a polygamous marriage had her own separate tent.  Laban found nothing. Then he went into Rachel's tent, where the teraphim were hidden. What he did not know was that Rachel had hidden them in the saddlebags of her camel. She greeted her father respectfully but did not rise from where she was sitting. She explained modestly that she could not do so, since she was menstruating.     'Let not my lord be angry that I cannot rise before you, for the way of women is upon me.'This meant that the cloth on which she was sitting was ritually unclean, and could not be touched by anyone. Most ancient tribes had customs that allowed menstruating women to withdraw from physical contact with the tribe while they had their periods, and women welcomed this time of rest from their usual tasks. Rachel's manner towards her father was so sweet and yielding that Laban did not argue or tell her to move, and the upshot was that he left her tent empty-handed. She had used the laws of ritual cleanliness to her own advantage. The irony was that it was a lie. She was already pregnant with a son.Since Laban could not find the teraphim, he had to back down. The two men made a face-saving covenant, and early the next morning Laban said good-bye to them all, and left.When Laban was gone Rachel's family moved on, and on the way to Ephrath she went into labor. This time things did not go well for her. The pains were very bad, and Rachel suffered terribly. To comfort her, the midwife told her it would be a boy. It was, but Rachel would not live to see him grow. She died in childbirth.  Join me as we go Chapter by Chapter, Verse by Verse, Unraveling the Words of Yahweh!Have any questions? Feel free to email me; keitner2024@outlook.com

The 159th Gilead Graduation features Governing Body member David Splane telling Jehovah's Witnesses to give each other the benefit of the doubt. He does this by encouraging us to be like... LOT?! Yes.... that Lot. TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast

El zamorano David Muñoz Mateos ha presentado en la Biblioteca Antonio Martínez Asensio de Hoy por Hoy su novela 'Entre hojas escondido' (Muñeca infinita). La narración nos traslada a las remotas tierras de la Sierra de la Culebra, en plena raya entre España y Portugal. Allí sitúa una acción protagonizada por Samuel,  un adulto que de niño fue abandonado en el bosque y convivió con los lobos. Muñoz Mateos , a partir de esta historia de infancia feral, nos cuenta como se adapta, o no, a la civilización Samuel , y a la vez hace una gran elegía del entorno natural de la culebra cada vez más abandonado por el ser humano, invadido por la naturaleza y víctima de los incendios.  Una novela brutal para nuestro bibliotecario Antonio Martínez Asensio que arrancó contando un cuento en tres minutos un cuento a José Luis Sastre, concretamente “El encaje roto” de Emilia Pardo Bazán que está dentro del volumen 'el encaje roto: Antología de cuentos de violencia contra las mujeres" de Emilia Pardo Bazán, editado por Contraseña. Luego añadiría el libro que nos contará en su programa "Un libro, una hora"  que será  'El tumulto de las bestias' de Ykio Mishima (Alianza Editorial). Nuestro invitado David Muñoz Mateos nos donó para nuestras estanterías una gran tetralogía , la de Marilynne Robinson, compuesta por 'Gilead', 'En casa', 'Lila' y 'Jack' (Galaxia Gutenberg). Las novedades las trajo Pepe Rubio y fueron dos:  'Los falsarios' de Adolfo García Ortega (Impedimenta) y 'La bola' de Daniel Verdú (Alfaguara). Pascual Donate volvió a rescatar un libro abandonado en la redacción de la SER , en este caso  'Telégrafos del estado' de  Matilde Serao (Editorial Espinas). Y finalmente las donaciones de los oyentes que fueron : 'Las ovejas detectives' de Lionie Swann (Salamandra) , 'Inés y la alegría' de Almudena Grandes (Tusquets) y 'Empresas y tribulaciones de Maqroll el gaviero' de Álvaro Mutis (Alfaguara) . 

Why did Cleopatra demand the balsam groves of Jericho as the price of financing Marc Antony's wars — and what does it mean that a plant worth twice its weight in gold was guarded day and night by Roman soldiers after the conquest of Jerusalem? What was the balm of Gilead, the most expensive agricultural commodity in the ancient world, and why did it grow nowhere on Earth except the shores of the Dead Sea? And how does a thousand-year-old seed, germinated in a Jordanian valley in 2024, connect the ancient world to the present?Join John and Patrick as they tell the story of Jordan — the asphalt wars, Cleopatra's monopoly, and the extinct plant that Roman soldiers fought to protect...----------In Sponsorship with J&K Fresh.The customs broker who is your fruit and veggies' personal bodyguard. Learn more here!-----------Join the History of Fresh Produce Club for ad-free listening, bonus episodes, book discounts and access to an exclusive chatroom community.Support us!Share this episode with your friendsGive a 5-star ratingWrite a review-----------Subscribe to our biweekly newsletter here for extra stories related to recent episodes, book recommendations, a sneak peek of upcoming episodes and more.-----------Instagram, TikTok, Threads:@historyoffreshproduceEmail: historyoffreshproduce@gmail.com

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this final episode of the ICH Quality series, we walk through the most important concepts in ICH Q14 and how they fit into the broader ICH quality framework.Rather than reviewing the guideline section by section, this episode focuses on the ideas that are most useful in practice: Why does ICH Q14 start with the Analytical Target Profile (ATP)? How is it different from ICH Q2? How do you develop analytical procedures using a science- and risk-based approach? And what does all of this have to do with ICH Q12 and lifecycle management?One quick note: at the time of recording, ICH Q14 remains under public comment, so some details may evolve before the final version is adopted.Chapters00:00 – Intro and ICH Q14 vs. Q201:08 – The Analytical Target Profile (ATP)04:16 – The Analytical Procedure Lifecycle05:32 – Risk-Based Development and Enhanced Approaches06:20 – Where ICH Q2 Fits: Validation08:04 – Connecting Q14 to ICH Q12 and Lifecycle Management09:22 – Closing the ICH Quality SeriesIn this episode, we cover:• Why ICH Q14 exists• The difference between ICH Q14 and ICH Q2• What an Analytical Target Profile (ATP) is• ATP examples and performance criteria• Technology selection and fit-for-purpose methods• The analytical procedure lifecycle• Risk assessments and enhanced development approaches• Multivariate experiments and DOE concepts• Analytical procedure control strategies• Validation and the role of ICH Q2• Lifecycle management of analytical procedures• The connection between ICH Q14 and ICH Q12• Why understanding matters more than simply checking a boxIf you've followed along through the ICH Quality series, one of the themes that keeps showing up is that quality isn't something you test into products at the end. Whether we're talking about Q8, Q9, Q10, Q12, or now Q14, the emphasis continues to shift toward building knowledge, understanding risk, and using that understanding throughout the lifecycle.Subhi Saadeh is the Founder and Principal at Let's Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, speaker, and host of the Let's Combinate podcast, with experience across companies including Pfizer, Gilead, and Baxter supporting vaccines, biologics, generics, and combination products.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Sermon TextGenesis 2:15–25; Song of Solomon 4:1–7; 1 Corinthians 6:9–11 (ESV)The Lord God took the man and put him in the garden of Eden to work it and keep it. And the Lord God commanded the man, saying, You may surely eat of every tree of the garden, but of the tree of the knowledge of good and evil you shall not eat, for in the day that you eat of it you shall surely die.Then the Lord God said, It is not good that the man should be alone; I will make him a helper fit for him. Now out of the ground the Lord God had formed every beast of the field and every bird of the heavens and brought them to the man to see what he would call them. And whatever the man called every living creature, that was its name. The man gave names to all livestock and to the birds of the heavens and to every beast of the field. But for Adam there was not found a helper fit for him.So the Lord God caused a deep sleep to fall upon the man, and while he slept took one of his ribs and closed up its place with flesh. And the rib that the Lord God had taken from the man he made into a woman and brought her to the man. Then the man said,This at last is bone of my bonesand flesh of my flesh;she shall be called Woman,because she was taken out of Man.Therefore a man shall leave his father and his mother and hold fast to his wife, and they shall become one flesh. And the man and his wife were both naked and were not ashamed.Behold, you are beautiful, my love, behold, you are beautiful! Your eyes are doves behind your veil. Your hair is like a flock of goats leaping down the slopes of Gilead. Your teeth are like a flock of shorn ewes that have come up from the washing, all of which bear twins, and not one among them has lost its young. Your lips are like a scarlet thread, and your mouth is lovely. Your cheeks are like halves of a pomegranate behind your veil. Your neck is like the tower of David, built in rows of stone; on it hang a thousand shields, all of them shields of warriors. Your two breasts are like two fawns, twins of a gazelle, that graze among the lilies. Until the day breathes and the shadows flee, I will go away to the mountain of myrrh and the hill of frankincense. You are altogether beautiful, my love; there is no flaw in you.Or do you not know that the unrighteous will not inherit the kingdom of God? Do not be deceived: neither the sexually immoral, nor idolaters, nor adulterers, nor men who practice homosexuality, nor thieves, nor the greedy, nor drunkards, nor revilers, nor swindlers will inherit the kingdom of God. And such were some of you. But you were washed, you were sanctified, you were justified in the name of the Lord Jesus Christ and by the Spirit of our God.Genesis 2:24Therefore a man shall leave his father and his mother and hold fast to his wife, and they shall become one flesh.1 Corinthians 6:15–17Do you not know that your bodies are members of Christ? Shall I then take the members of Christ and make them members of a prostitute? Never! Or do you not know that he who is joined to a prostitute becomes one body with her? For, as it is written, The two will become one flesh. But he who is joined to the Lord becomes one spirit with him.Proverbs 5:18–19Let your fountain be blessed, and rejoice in the wife of your youth, a lovely deer, a graceful doe. Let her breasts fill you at all times with delight; be intoxicated always in her love

THE TESTAMENTS – “Secateurs” – While Becka faces the consequences of her actions, Agnes and Daisy must decide how far they're willing to go to protect her. (Disney/Steve Wilkie)LUCY HALLIDAY, CHASE INFINITI, ROWAN BLANCHARD Gilead's history is being re-written, and the resistance is wearing school green. In this jam-packed season finale breakdown, Paul and Caroline dive deep into “Secateurs,” an episode that changes the game for every major player. From high-stakes smuggling operations to heartbreaking sacrifices, we analyze a finale that feels less like an ending and more like the birth of an army. THE TESTAMENTS – “Secateurs” – While Becka faces the consequences of her actions, Agnes and Daisy must decide how far they're willing to go to protect her. (Disney/Steve Wilkie)ELISABETH MOSS

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligence, particularly through custom models like Chai-3, this partnership aims to revolutionize drug discovery. The integration of AI promises not only to accelerate the identification of biologics and antibodies but also to optimize resource allocation in research and development. Such technological integration could pave the way for an enhanced pipeline of innovative treatments, marking a transformative shift in how therapeutic candidates are developed. In the realm of regulatory developments, Lupin's Ranluspec has recently received FDA approval as an interchangeable biosimilar targeting VEGF-A for various retinal conditions. This move underscores the importance of biosimilars in providing cost-effective alternatives to expensive biologics, thereby expanding patient access to essential treatments for conditions like macular degeneration. Additionally, the MHRA's marketing authorization for Aujemflu, an adjuvanted trivalent influenza vaccine for adults aged 50 and over, reflects ongoing efforts to bolster protection against infectious diseases among vulnerable populations. Clinical trial advancements continue to highlight significant progress in therapeutic development. Otsuka Pharmaceuticals' Phase 3 data on Voyxact has shown promising stabilization of kidney function in patients with Immunoglobulin A nephropathy. This protein therapy targets autoimmune pathways, offering new hope for managing this chronic kidney condition. Similarly, Autobahn Therapeutics' Elunetirom has advanced to a pivotal trial following Phase 2 success in treating bipolar depression. This showcases the potential of small molecule therapies targeting thyroid hormone receptors. Meanwhile, Hikma Pharmaceuticals' victory in a landmark patent case regarding skinny labels marks an important development in pharmaceutical intellectual property rights. The unanimous Supreme Court ruling against Amarin supports the legitimacy of using skinny labels to market generic versions of drugs for non-patented indications. This decision could enhance market competition and drive down healthcare costs, setting a precedent for future intellectual property disputes. On the business front, strategic partnerships and mergers continue to shape industry dynamics. Gilead Sciences' acquisition of Ouro Medicines for $1.675 billion strengthens its autoimmune inflammation pipeline. This transaction exemplifies how major deals are reshaping therapeutic portfolios in response to growing demand for treatments targeting rare diseases. Financially, Solix Pharmaceuticals' success in raising $71 million to advance its siRNA pipeline across multiple therapeutic areas demonstrates investor confidence in RNA-based therapeutics as a promising frontier for innovative treatments. Conversely, challenges persist as evidenced by Takeda's $2.5 billion legal provision over an antitrust case related to Amitiza, underscoring ongoing financial risks associated with litigation in the pharmaceutical sector. Corporate restructuring also signals shifts within the industry landscape. Fulcrum Therapeutics' decision to lay off 85% of its workforce following the discontinuation of its sickle cell disease candidate highlights the volatility and high stakes inherent in drug development. Overall, these developments illustrate a dynamic landscape where scientific innovation is propelled by AI-driven approaches and strategic collaborations while regulatory victories and financial maneuvers shape market dynamics. These trends have profound implications for patient care by potentially accelerating the availability of novel therapies and fostering a competitive environment that drives down costs. As we look ahead, stakeholders must navigate these complexities effectively to harness opportunities and address challenges within this rapidly evolving industry landscape. The ability to adapt and capitalize on emerging trends will be crucial as these sectors continue to evolve, ultimately enhancing patient care and advancing therapeutic frontiers globally. Thank you for joining us today on Pharma Daily; stay tuned for more insights into the ever-changing world of pharmaceuticals and biotech.Support the show

In this Bible Story, the great reign of David came to a close. Now Solomon rules over Israel with wisdom, mercy, and justice. As his first act as king, Solomon takes care of those who were loyal to his father, and deals justly with those who betrayed him. This story is inspired by 1 Kings 2. Go to BibleinaYear.com and learn the Bible in a Year.Today's Bible verse is 1 Kings 2:45 from the King James Version.Episode 113: As David is dying, he calls in his son Solomon to bless him and speak God's promises over him. David instructs him on what he should do with Joab and Shimei and requests that he show kindness to Barzillai of Gilead. But Adonijah was not done trying for the throne. He made a request of Bathsheba that Solomon rightly discerned as a claim to the throne. And so as per their agreement, he was executed. Solomon sought to rule his kingdom in fairness and enacted punishments that showed mercy to those who deserved death.Hear the Bible come to life as Pastor Jack Graham leads you through the official BibleinaYear.com podcast. This Biblical Audio Experience will help you master wisdom from the world's greatest book. In each episode, you will learn to apply Biblical principles to everyday life. Now understanding the Bible is easier than ever before; enjoy a cinematic audio experience full of inspirational storytelling, orchestral music, and profound commentary from world-renowned Pastor Jack Graham.Also, you can download the Pray.com app for more Christian content, including, Daily Prayers, Inspirational Testimonies, and Bedtime Bible Stories.Visit JackGraham.org for more resources on how to tap into God's power for successful Christian living.Pray.com is the digital destination of faith. With over 5,000 daily prayers, meditations, bedtime stories, and cinematic stories inspired by the Bible, the Pray.com app has everything you need to keep your focus on the Lord. Make Prayer a priority and download the #1 App for Prayer and Sleep today in the Apple app store or Google Play store.Executive Producers: Steve Gatena & Max BardProducer: Ben GammonHosted by: Pastor Jack GrahamMusic by: Andrew Morgan SmithBible Story narration by: Todd Haberkorn Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Gilead elders make an offer to Yiftach

Reposted from The Handmaid's Tale Podcast: The Testaments, which you can find and subscribe to at: https://podcastica.com/podcast/the-handmaids-tale-podcast  — What a thrill to once again talk to Bruce Miller, showrunner of The Testaments! His enthusiasm for the material is clear and infectious, and we hope you enjoy the conversation as much as we did. Among other things, Bruce talked about: Why Gilead is terrified of teenage girls Rowan Blanchard's performance as Shunammite, and why he thinks viewers eventually came around on the character Lydia's motivations, including whether she really believed she was protecting the women of Gilead The brutal stadium flashback, and the challenge of adapting such disturbing material without making viewers turn away What Agnes remembers about her mother, and how Gilead may have manipulated the memories of stolen children The cameos from Handmaid's Tale characters, and whether he thinks more of The Handmaid's Tale cast would want to return The visual storytelling of the series, from production design and costumes to color and cinematography Why we saw so little red this season What it was like working with the remarkable young cast Some intriguing hints about season two, including character backstories and a possible Gilead road trip And a lot more! Check out our other podcasts: If you like our coverage of The Testaments, we cover many other shows on our network at podcastica.com.  Learn more about your ad choices. Visit megaphone.fm/adchoices

“The Lord will never give us up as long we keep coming back to Him.” That's what Dr. McGee shares as we see Jacob and his family flee to Mt. Gilead with Laban and his brothers in hot pursuit. What happens next? Join as the story unfolds.

Join me as I discuss the season one finale of The Testaments, S1 E10, Secateurs, with Andy.

Reposted from The Handmaid's Tale Podcast: The Testaments, which you can find and subscribe to at: https://podcastica.com/podcast/the-handmaids-tale-podcast  — A moving, satisfying, bittersweet season finale where these girls who've spent the season waking up to how oppressed they and the women of Gilead have been decided to take a stand. We loved it, and we have a lot to talk about.  A huge thank you to everyone who listened and who wrote or called in. It's been a fantastic season of podcasting, and we really loved sharing the experience of this great new show with you guys!  We've got one more episode left to go. We had intended on including all your feedback in this episode, but as we should've known, there's more than enough for a standalone episode, so that should be out sometime next week. Talk to you then.  Mentioned:  Bruce Miller interviewed by The Hollywood Reporter: https://www.hollywoodreporter.com/tv/tv-features/the-testaments-finale-creator-promises-june-hannah-reunion-1236606878/ Next up: Listener feedback for The Testaments S1E10 “Secateurs”. Let us know your thoughts! You can email or send a voice message to testify@podcastica.com. Or check out our Handmaid's Tale: Mayday Facebook group, where we put up comment posts for each episode, at facebook.com/groups/thtmayday. Or join our Discord where you can leave comments and chat with hosts and other listeners: https://discord.gg/6WUMt3m3qe  Check out our other podcasts: If you like our coverage of The Testaments, we cover many other shows on our network at podcastica.com.  Digging our podcast? A quick, free, and easy way to show support and help bump us up in the charts is to give us a rating or a review: On Apple Podcasts: https://podcasts.apple.com/us/podcast/the-handmaids-tale-podcast-the-testaments/id1610222002 On Spotify: https://open.spotify.com/show/5MbAApyqlk3gLJUTHNnIH9?si=74013f9e35c64f0e Or just search for “Podcastica Testaments” wherever you get podcasts.  Show support and get ad-free episodes and a bunch of other cool stuff: patreon.com/jasoncabassi  Or go to buymeacoffee.com/cabassi for a one-time donation. Thank you! Learn more about your ad choices. Visit megaphone.fm/adchoices

Text us your questions!Randy and Kyle sit down with Milwaukee pastor and author Matt Erickson to explore a different vision of pastoral ministry: not the pastor as CEO, brand manager, or religious expert, but the pastor as gardener. Matt's book, The Pastor as Gardener: A Renewed Vision for Ministry, grows out of real ministry pressure, including moral failures, church decline, the pandemic, and the strain of navigating racial justice and polarization in a multiracial congregation.We dig into why agrarian imagery in Scripture still has bite for modern life, even in an urban church context. The gardener metaphor reframes leadership around cultivation instead of control: planting and watering while admitting we can't manufacture growth. That shift changes what we celebrate, what we fear, and what we measure, especially when the visible “fruit” of ministry looks strong but the hidden “roots” of prayer, integrity, and interior life are neglected.From there, we talk about what shepherding can still mean today, why care for the sick and grieving often gets delegated away, and why pastors need space to evolve without being treated like they've failed. Along the way we touch Gregory of Nyssa, Marilynne Robinson's Gilead, and the pressure for pastors to project certainty in a world where nobody can be an expert at everything.Look for Part 2 of this conversation in a couple weeks.=====Want to support us?The best way is to subscribe to our Patreon. Annual memberships are available for a 10% discount.If you'd rather make a one-time donation, you can contribute through our PayPal.Other important info:Rate & review us on Apple & SpotifyFollow us on social media at @PPWBPodcastWatch & comment on YouTubeEmail us at pastorandphilosopher@gmail.comCheers!

On episode #107 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 5/7 – 5/20/26. Host: Daniel Griffin and Sarah Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) (Gileadl) A Phase 3, Randomized Trial ofBulevirtide in Chronic Hepatitis D(NEJM) Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) (NLM: ClinicalTrials.gov) Andes Hantavirus Outbreak on a Cruise Ship, 2026 (NEJM) Quick takes: Another hantavirus case, polio in 3 countries, NIAID head steps down (CIDRAP) Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial (CID) Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy (CID) Use of Dolutegravir for treatment of HTLV-1 (CID) Use of dolutegravir to treat people living with HTLV-1-associated myelopathy (HAM) (CID) Bacterial Urinary Tract Infection (UTI)-free and Recurrent UTI (rUTI)-Free Survivals Following Bladder Electrofulguration in Women With a History of Antibiotic-Refractory rUTI (OFID) Azithromycin for Preschoolers with Wheezing in the Emergency Department (JAMA) Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care (JAMA Internal Medicine) Fungal The Last of US Season 2 (YouTube) Changes in Epidemiology of Candidemia in the United States With a Focus on Candida auris (CID) Parasitic Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme (The LANCET) Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement  (JAMA Network OPEN) Febrile Temperature Augents Ring-stage Plasmodium falciparum Adhesion to Brain Endothelial Cells (JID) An Increase in Imported Plasmodium vivax Malaria in New York City: Clinical and Demographic Trends Following Recent Migration (OFID) Miscellaneous The State of Physician Leadership (WittkKieffer) Infectious Diseases Fellowship Curriculum: IDSA Training Program Directors Community of Practice (TPDCOP), Curricular and Educational REsources Workgroup (CREW) (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Dive into the bold, emotional, and revealing finale of The Testaments, where truths surface, identities shift, and long-standing connections come full circle in powerful ways. Diana and Sam break down the biggest character moments, emotional turning points, and the rising strength of the women pushing against Gilead's system. In This Episode: Character growth and shifting perspectives throughout the finale Agnes discovering the truth about her identity Daisy, June, and Agnes' deeply connected journey Becca's heartbreaking storyline and devastating sacrifices Women influencing women and challenging oppressive systems Aunt Lydia's evolving perspective and internal conflict Resistance, rebellion, and the rising courage of the younger generation Connections to The Handmaid's Tale and the larger universe Hope, change, sacrifice, and what the finale sets up moving forward (00:00) - Welcome & episode overview (01:00) - Initial reactions & finale insights (03:00) - Agnes learns the truth about her identity (06:30) - Daisy and June's bonding & revelations (07:00) - Daisy confronts Agnes about her true identity (09:00) - Women influencing women & shifting power dynamics (10:00) - Agnes confronts Aunt Vidala (11:00) - Aunt Vidala tells Lydia she doesn't have to be alone (12:00) - The girls losing innocence but gaining agency (13:00) - Aunt Lydia feels the weight of responsibility (15:00) - Agnes challenges everyone to help Becca (17:00) - Resistance, rebellion & collective female power (21:00) - Becca's heartbreaking storyline (25:00) - Becca's wedding intercut with her mother's sacrifice (28:30) - The indifference of Gilead's men (29:50) - Agnes and Becca's melancholy kiss (31:50) - June and Garth react to Daisy's actions (34:30) - Agnes' awakening: the truth about her mother (38:30) - Reflections on the season: hope, change & transformation (40:49) - Question of the Day (46:50) - TV & movie recommendations alt-J - Hunger Of The Pin:  https://www.youtube.com/watch?v=dCCXq9QB-dQ Website: www.screensinfocus.comEmail: screensinfocus@gmail.com Instagram: @screensinfocusFacebook: Screens in FocusTikTok: Screens in FocusYouTube: Screens in Focus Feedback and TV/Movie Recommendations: Google Voice: (669) 223-8542 Free background music from JewelBeat.com: www.jewelbeat.com  

The 1800s was an era when medicine sat at the crossroads of science, ruses and discoveries. New vaccines and medical impostors competed for public trust. People broke with tradition and created a new landscape. Mordecai Wolff Haffkine Haffkine stood out as an almost legendary figure. A Jewish bacteriologist, he developed and tested vaccines against cholera and bubonic plague, putting his life repeatedly at risk and fighting to save the lives of millions of people. Whereas Dr. Samuel Solomon showed how skilful wording and suggestion could build a reputation and a fortune. Although his contribution to public service is rather unknown, Liverpool remembers him to this day - on par with some of their other legends. We also look at what happens when medicine and surgery produce unexpected outcomes. What are the halachic ramifications? And how did the BBC cover a re-election campaign in Kentucky?   Timestamps: - 0:00:00–0:00:31 — Opening advertisement read (Dr. Solomon). - 0:00:31–0:03:47 — Hosts intro: series overview and upcoming guests. - 0:03:47–0:08:36 — Start of Mordechai Wolf Hafkin biography (education, expulsion, Pasteur Institute). - 0:08:36–0:12:33 — Hafkin self‑inoculates and early cholera vaccine work. - 0:12:33–0:15:43 — Hafkin's large vaccination campaigns in India; plague vaccine development. - 0:15:43–0:23:00 — Political opposition, 1902 tetanus deaths, inquiry and character attack. - 0:23:00–0:31:44 — Scientific exoneration, later life, return to Orthodoxy, philanthropy, death (1930). - 0:31:44–0:45:06 — Dr. Samuel Solomon biography: origins, balm of Gilead, marketing, bought MD. - 0:45:06–0:46:44 — Solomon's social status, legacy, and mixed moral assessment. - 0:46:44–0:53:33 — Halachic case: wrong‑kidney removal that saved the patient; discussion of intent vs. outcome and liability. - 0:53:33–0:58:34 — Media segment: critique of BBC coverage of Thomas Massie's election loss. - 0:58:34 — Episode close; call for listener feedback (podcast@jle.org.uk) and preview of part 2.

The Guilty Feminist 483. The Epstein Files with The Nerve Presented by Deborah Frances-White and Ria Lina with special guests Carole Cadwalladr and Lucia Osborne-Crowley from The Nerve, poetry from Dan Whitlam and music from GeeJay Recorded 30 April 2026 at the Leicester Square Theatre in London. Released 18 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Ria Lina https://www.instagram.com/rialina_ https://www.patreon.com/cw/rialina https://rialina.com More about The Nerve https://www.instagram.com/the_nerve_news https://www.thenerve.news https://www.instagram.com/carole_cadwalladr More about Lucia Osborne-Crowley https://www.instagram.com/luciaoc https://luciaosbornecrowley.com https://www.waterstones.com/book/the-lasting-harm/lucia-osborne-crowley/9780008591229 More about Dan Whitlam https://www.instagram.com/danwhitlam https://www.danwhitlam.com More about GeeJay https://www.instagram.com/geejayuk https://geejay.uk https://soundcloud.com/geejayuk For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Tracey Emin in Conversation. https://www.southbankcentre.co.uk/whats-on/the-guilty-feminist-tracey-emin-in-conversation/ Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Guilty Feminist 483. The Epstein Files with The Nerve Presented by Deborah Frances-White and Ria Lina with special guests Carole Cadwalladr and Lucia Osborne-Crowley from The Nerve, poetry from Dan Whitlam and music from GeeJay Recorded 30 April 2026 at the Leicester Square Theatre in London. Released 18 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Ria Lina https://www.instagram.com/rialina_ https://www.patreon.com/cw/rialina https://rialina.com More about The Nerve https://www.instagram.com/the_nerve_news https://www.thenerve.news https://www.instagram.com/carole_cadwalladr More about Lucia Osborne-Crowley https://www.instagram.com/luciaoc https://luciaosbornecrowley.com https://www.waterstones.com/book/the-lasting-harm/lucia-osborne-crowley/9780008591229 More about Dan Whitlam https://www.instagram.com/danwhitlam https://www.danwhitlam.com More about GeeJay https://www.instagram.com/geejayuk https://geejay.uk https://soundcloud.com/geejayuk For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Tracey Emin in Conversation. https://www.southbankcentre.co.uk/whats-on/the-guilty-feminist-tracey-emin-in-conversation/ Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Guilty Feminist 483. Bonus Presented by Deborah Frances-White with special guest Lucia Osborne-Crowley from The Nerve Recorded 13 May 2026 via Riverside. Released 18 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Lucia Osborne-Crowley https://www.instagram.com/luciaoc https://luciaosbornecrowley.com https://www.waterstones.com/book/the-lasting-harm/lucia-osborne-crowley/9780008591229 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Tracey Emin in Conversation. https://www.southbankcentre.co.uk/whats-on/the-guilty-feminist-tracey-emin-in-conversation/ Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Listen to the rest of this premium episode by subscribing at patreon.com/knowyourenemy. As always, listeners asked more mailbag questions than we could respond to in one episode, so we continue answering them here for subscribers. In this second round we take up: a playlist of KYE's Straussian-related episodes; (Straussian) esoteric writing versus (French) death of the author and the art of writing (and interpretation); prose style—what it is, why it matters, its relationship to poetry, and the rhythms of Norman Maclean; a "Straussian" reading of Steely Dan; and why liberalism is (mostly) worth defending. Thank you to everyone who attended our live event in NYC on Thursday! We had a great time.  Sources: Leo Strauss, Persecution and the Art of Writing (1952) — Thoughts on Machiavelli (1958) Stanley Rosen, Hermeneutics as Politics (1987) Wallace Stevens, "The Snow Man," Poetry, Oct 1921 Norman Maclean, A River Runs Through It and Other Stories (1976) — The Norman Maclean Reader (2008) Edmund White, Nocturnes for the King of Naples (1978) Marilynne Robinson, Gilead (2004) W.H. Auden, "Friday's Child," (1958) Sam Adler-Bell, "Can Liberalism Stop Being So Darn Liberal?" The New Republic, June 20, 2024.

The Promised Land You Can't Enter Yet by Autumn Dickson In the chapters this week, Moses is led to the top of a mountain where he is shown the promised land. Deuteronomy 34: 1, 4 1 And Moses went up from the plains of Moab unto the mountain of Nebo, to the top of Pisgah, that is over against Jericho. And the Lord shewed him all the land of Gilead, unto Dan… 4 And the Lord said unto him, This is the land which I sware unto Abraham, unto Isaac, and unto Jacob, saying, I will give it unto thy seed: I have caused thee to see it with thine eyes, but thou shalt not go over thither. Interestingly enough, despite the fact that the Lord led him there to show him the promised land, Moses wasn't allowed to go into the promised land because of prior disobedience. He had led the Israelites out of Egypt and across the wilderness. It had not been easy. At one point, Moses had even asked the Lord to kill him rather than deal with the Israelites anymore. Moses suffered plenty of hardship, and he learned many great and important lessons. But despite this, Moses was still not allowed to step foot in the promised land. The Lord held true to Moses' consequences for disobedience. According to modern revelation, Moses was translated and taken up to the Lord before the Israelites entered the homeland that was meant for them. Details are always key. One of the details this week is the fact that Moses was taken up into a mountain where he could overlook the promised land that he couldn't enter. Mountains in scripture are often compared to temples. Holy things often take place on the tops of mountains, and the Lord gives knowledge and power to some of His children in the tops of mountains. Hold that thought. I wonder how he felt looking over the lands that were meant to be the inheritance of the Israelites. Did it hurt him that he would not be joining them or had he come to terms with the consequences that had been laid out for his disobedience? Did it hurt to see what had been meant to be his inheritance? Did it hurt to see the promises of the Lord that he would not be receiving? Whether it hurt or not, I can assure you that it no longer hurts Moses. He was translated, and he ended up in a different promised land than he had pictured or seen on the top of that mountain. It was a better promised land. Yes, Moses is just fine. I have found a surprising pattern in my life. I have multiple friends who dislike the temple, not because they don't agree with what happens there, but because they can't see the promises of the Lord being fulfilled for them. I have friends who have faced infidelity or family members who don't want to participate in ordinances in the the temple. Going to the temple and hearing the promises that were meant to be theirs doesn't feel particularly good. It is painful to hear about it and desire it deeply and not have current access to it. I fully recognize that I have not been in their shoes, nor do I understand what it's like to feel barred from those promises. Even as I share my testimony of these things, I fully own that I dont understand what it's like to have to come to terms with feelings like that. But sometimes objectivity is precisely what is needed. Strong emotions can be so overwhelming that it's difficult to see the end from the beginning. So let me testify of the end. Moses did not enter into that promised land here. He could see it. He was so close, but it was something that wasn't available to him. I promise you that he's okay. More than that, I promise that he is far more than okay. The Lord has taken care of Moses beautifully. There are two specific promises I want to testify of if you are facing the same problem as Moses or my friends. If you feel that there is no happy ending in sight, these are the promises I want you to hold to. Promise one. There is a promised land available for you even if it feels like mortality is barring you from in it one form or another. Mortality is not strong enough to keep you from your Savior's ability to give you a joyful existence. He is mighty to save. He can take care of you. You are not actually barred from those promises. And in all honesty, you don't even have to wait to step foot in the promised land. Moses' disobedience was what kept him from the promised land, and even his own disobedience didn't ultimately keep him from eternal joy. If you feel innocently barred, then Satan is lying to you. Christ can offer peace and comfort right now. You can go to the temple and listen to the promises and cling to them. Find comfort in them. You don't have to know the how in order for those promises to take affect in your life. Those promises ARE for you even if you don't know exactly how they will look. And if you don't feel strong enough to cling to those promises, He has the power to bring peace even when it's illogical. You can go to the temple and call upon the blessings He promised you there. You can tell Him, “I'm here. I came like You asked. Can you help me feel peace?” And then allow Him to offer peace. Allow Him to comfort you. Unfortunately, sometimes promises of joy feel empty without our loved ones who refuse their own promises. Which brings me to promise two. The Lord can take care of those around us, just as He can take care of you. Elder Orson F. Whitney, an apostle, taught this: The Prophet Joseph Smith declared—and he never taught a more comforting doctrine—that the eternal sealings of faithful parents and the divine promises made to them for valiant service in the Cause of Truth, would save not only themselves, but likewise their posterity. Though some of the sheep may wander, the eye of the Shepherd is upon them, and sooner or later they will feel the tentacles of Divine Providence reaching out after them and drawing them back to the fold. Either in this life or the life to come, they will return. I don't believe the sealing power only applies to children. There is a reason we all get sealed together; I believe this likewise applies to spouses who have chosen to stray. The Lord has a plan for everyone who ever lived upon the earth to be sealed together. That sealing power is so strong. And in the meantime, He will sorrow with you. He knows what it's like to watch loved ones stray. He cannot force them to come back, but He knows how to succor you in your pain. He knows exactly how you feel, probably even stronger because His love is deeper. Take comfort in the fact that He has found eternal joy and hope. You can too. Looking at the promised land doesn't have to feel painful. I testify that if Moses had seen what was coming for him, any sting from being barred from the promised land would have been soothed. It would have had no power because Moses knew what the Lord had in store for him. We can be like Moses. If you could see the end, it would take away much of the sting for you as well. I testify that as we consciously strive to strengthen our testimonies of His promises, we find the balm He promised us now, not just in the next life. I testify that the Savior can deliver on His promises of eternal joy. I testify that the ending is beautiful. I testify that He knows how to reach our loved ones, and we can trust Him with them. Autumn Dickson was born and raised in a small town in Texas. She served a mission in the Indianapolis Indiana mission. She studied elementary education but has found a particular passion in teaching the gospel. Her desire for her content is to inspire people to feel confident, peaceful, and joyful about their relationship with Jesus Christ and to allow that relationship to touch every aspect of their lives. Autumn was the recipient of FAIR's 2024 John Taylor Defender of the Faith Award. The post Come, Follow Me with FAIR – Deuteronomy 6–8; 15; 18; 29–30; 34 – Part 2 – Autumn Dickson appeared first on FAIR.

The Guilty Feminist Culture Club: Yesteryear Presented by Deborah Frances-White and very special guest Caro Claire Burke Recorded 28 April 2026 in London. Released 14 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Caro Claire Burke https://www.caroclaireburke.com https://www.waterstones.com/book/yesteryear/caro-claire-burke/9780008742768 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 482. Ten for Ten #10 Presented by Deborah Frances-White with special guest Sara Pascoe Recorded 9 April 2026 in London. Released 11 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Sara Pascoe https://www.instagram.com/sara.pascoe https://sarapascoe.co.uk For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 481. The Algorithm Presented by Deborah Frances-White, guest co-host Aoife Dunne and guest Adele Zeynep Walton Recorded 10 April 2026 at the Museum of Comedy in London. Released 4 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Aoife Dunne https://www.instagram.com/aoife_is_never_dunne https://aoifedunnecomedy.com More about Adele Zeynep Walton https://www.instagram.com/adele_walton https://www.adelesnotes.co.uk https://www.waterstones.com/book/logging-off/adele-zeynep-walton/9781398722927 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 481. The Algorithm Presented by Deborah Frances-White, guest co-host Aoife Dunne and guest Adele Zeynep Walton Recorded 10 April 2026 at the Museum of Comedy in London. Released 4 May. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about Aoife Dunne https://www.instagram.com/aoife_is_never_dunne https://aoifedunnecomedy.com More about Adele Zeynep Walton https://www.instagram.com/adele_walton https://www.adelesnotes.co.uk https://www.waterstones.com/book/logging-off/adele-zeynep-walton/9781398722927 For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Guilty Feminist 480. Keep Palantir Out Of Our NHS Presented by Deborah Frances-White, guest co-host Susan Wokoma and guests Dr Matt Mahmoudi and Linnéa Freear Recorded 17 April 2026 at the Museum of Comedy in London. Released 27 April. The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-have Enter BLOODYPOWERFUL20 at check out for 20% off at www.cambridge.org/BloodyPowerful More about Deborah Frances-White https://deborahfrances-white.com https://www.instagram.com/dfdubz https://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811 https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120 More about our guests https://www.instagram.com/susiewoosie12 https://www.instagram.com/docmattmoudi https://patientsnotpassports.co.uk https://goodlawproject.org/campaign/stop-palantir-in-the-nhs https://www.healthworkers4palestine.com For more information about this and other episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT More Big Speeches workshops now available https://guiltyfeminist.com/big-speeches/ Come to a live show Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead/ Road to Gilead at the Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist/ The Guilty Feminist Meets Rose McGowan. https://www.charleston.org.uk/event/the-guilty-feminist Guilty Feminist at Ventnor Fringe. https://purchase.vfringe.co.uk/EventAvailability?EventId=37801 Edinburgh Fringe. https://tickets.gildedballoon.co.uk/event/14:6708/ Thank you to our amazing Patreon supporters. To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts. The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices